{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T08:17:31Z","timestamp":1794903451799,"version":"4.9.1"},"reference-count":77,"publisher":"Informa UK Limited","issue":"29","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Takeda Pharmaceuticals America, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,8]]},"DOI":"10.1080\/14796694.2025.2584290","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:20:47Z","timestamp":1762852847000},"page":"3799-3810","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Oncologists\u2019 preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment"],"prefix":"10.1080","volume":"21","author":[{"given":"Kathryn F.","family":"Mileham","sequence":"first","affiliation":[{"name":"Wake Forest University School of Medicine","place":["Charlotte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Panattoni","sequence":"additional","affiliation":[{"name":"Precision AQ","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Gahlon","sequence":"additional","affiliation":[{"name":"Precision AQ","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Labisa","sequence":"additional","affiliation":[{"name":"Takeda Farmac\u00eauticos Portugal","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bariahtaris","sequence":"additional","affiliation":[{"name":"Precision AQ","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Graf","sequence":"additional","affiliation":[{"name":"Precision AQ","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Danes","sequence":"additional","affiliation":[{"name":"Inc","place":["Lexington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Inc","place":["Lexington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_9_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_9_5_1","volume-title":"Cancer facts & figures","author":"Society AC.","year":"2025","unstructured":"Society AC. Cancer facts & figures. Atlanta: American Cancer Society; 2025."},{"key":"e_1_3_9_6_1","unstructured":"Lung cancer - non-small cell: statistics. 2021 [cited 2021 Aug 11]."},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e21586"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.09.010"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.12.014"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221126174"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810171"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027187"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795"},{"key":"e_1_3_9_14_1","volume-title":"NCCN clinical practice guidelines in oncology","author":"Non-Small Cell Lung Cancer, Version 3.2025","year":"2025","unstructured":"Non-Small Cell Lung Cancer, Version 3.2025. NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network; 2025."},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0025"},{"key":"e_1_3_9_16_1","unstructured":"[NICE] N.I.f.H.a.C.E. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer. 2023."},{"key":"e_1_3_9_17_1","unstructured":"[NICE] N.I.f.H.a.C.E. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer. 2018."},{"key":"e_1_3_9_18_1","unstructured":"[NICE] N.I.f.H.a.C.E. Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. 2021."},{"key":"e_1_3_9_19_1","unstructured":"[NICE] N.I.f.H.a.C.E. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. 2020."},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0396"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S248295"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S235430"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.653450"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/2381468320922208"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-018-0327-3"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S302394"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.689114"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0622-4"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1062830"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032336"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S224529"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13457"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.01.016"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1210"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.02.009"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11100998"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.602112"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-011-0683-0"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0348"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100157"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7836264"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-024-01359-x"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0734-2"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-024-01629-9"},{"key":"e_1_3_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_3_9_48_1","volume-title":"Treatment options for advanced non-small cell lung cancer: effectiveness, value and value-based price benchmarks. Final evidence report and meeting summary","author":"Review, I.f.C.a.E","year":"2016","unstructured":"Review, I.f.C.a.E. Treatment options for advanced non-small cell lung cancer: effectiveness, value and value-based price benchmarks. Final evidence report and meeting summary. Institute for Clinical and Economic Review; 2016."},{"key":"e_1_3_9_49_1","unstructured":"Health C.A.f.D.a.T.i. Pan-Canadian Oncology Drug Review final clinical guidance report: alectinib (Alecensaro) for non-small cell lung cancer. 2018."},{"key":"e_1_3_9_50_1","unstructured":"Health C.A.f.D.a.T.i. Cadth pcodr final clinical guidance report: clinical report - brigatinib (Alunbrig). 2021."},{"key":"e_1_3_9_51_1","unstructured":"Health C.A.f.D.a.T.i. Pan-Canadian Oncology Drug Review final clinical guidance report: lorlatinib (Lorbrena) for non-small cell lung cancer. 2020."},{"key":"e_1_3_9_52_1","unstructured":"Care I.f.Q.a.E.i.H. Iqwig reports \u2013 commission No. A17-67 Alectinib (non-small cell lung cancer) \u2013 benefit assessment according to \u00a735a Social Code Book V1 (new therapeutic indication). 2018."},{"key":"e_1_3_9_53_1","unstructured":"Care I.f.Q.a.E.i.H. Iqwig reports \u2013 commission no. A20-42 Brigatinib (non-small cell lung cancer) \u2013 benefit assessment according to \u00a735a Social Code Book V. 2020."},{"key":"e_1_3_9_54_1","unstructured":"Care I.f.Q.a.E.i.H. Iqwig reports \u2013 commission No. A22-31 lorlatinib (NSCLC) \u2013 benefit assessment according to \u00a735a Social Code Book V1. 2022."},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.035"},{"key":"e_1_3_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00437-4"},{"key":"e_1_3_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.007"},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.478"},{"key":"e_1_3_9_59_1","unstructured":"ALUNBRIG (Brigatinib): Prescribing information. [cited 2024 Feb 21]. Available from: https:\/\/www.alunbrig.com\/hcp\/sites\/default\/files\/2022-09\/pi.pdf"},{"key":"e_1_3_9_60_1","unstructured":"LORBRENA (Lorlatinib): Prescribing information. [cited 2024 Feb 21] Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11140#section-6"},{"key":"e_1_3_9_61_1","unstructured":"ALECENSA (Alectinib): Prescribing information. [cited 2024 Feb 21]. Available from: https:\/\/www.gene.com\/download\/pdf\/alecensa_prescribing.pdf"},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-638"},{"key":"e_1_3_9_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111805"},{"key":"e_1_3_9_64_1","volume-title":"Alg design","author":"Wheeler B","year":"2004","unstructured":"Wheeler B. Alg design. The R project for statistical computing; 2004."},{"key":"e_1_3_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijresmar.2005.09.003"},{"key":"e_1_3_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.11.005"},{"key":"e_1_3_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.07.876"},{"key":"e_1_3_9_68_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831"},{"key":"e_1_3_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.01.012"},{"key":"e_1_3_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_9_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.984"},{"key":"e_1_3_9_72_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S125245"},{"key":"e_1_3_9_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00894-7"},{"key":"e_1_3_9_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/0095798420930932"},{"key":"e_1_3_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.08.010"},{"key":"e_1_3_9_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9592-y"},{"key":"e_1_3_9_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30649-1"},{"key":"e_1_3_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107535"},{"key":"e_1_3_9_79_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.05.02"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2584290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2584290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2584290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:31:51Z","timestamp":1794900711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2584290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":77,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2025,12,8]]}},"alternative-id":["10.1080\/14796694.2025.2584290"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2584290","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}